63 results about "Clostridium organisms" patented technology

The invention provides a nano antibody of clostridium difficile glutamate dehydrogenase, and an encoding sequence, a screening method and the application thereof and belongs to the technical field ofimmunology. The invention provides an amino sequence of the nano antibody of clostridium difficile glutamate dehydrogenase. By using a phage display technology, a sequence with a constant region specific gene is inserted into a vector of a phage encoding coat protein, after recombination expression, an exogenous gene expression product is fused with the phage encoding coat protein and demonstratedon the surface of phage to form a phage demonstration library, phage monocloning of the nano antibody is expressed through screening, and the nano antibody is prepared through sequencing. Phage-ELLSAidentification shows that the phage that the nano antibody is expressed on the surface can be specifically combined with clostridium difficile glutamate dehydrogenase antigen and has a good developing property, the result shows that the nano antibody has a good combination property with glutamate dehydrogenase, therefore, the nano antibody can be adopted to replace a common antibody applied to aclostridium difficile immunodetection kit.

The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.

The invention discloses recombinant yeast chassis cell transformation for efficiently converting chenodeoxycholic acid and recombinant strain construction and application, a saccharomyces cerevisiae strain S. Cerevisiae CEN.PK21C is used as a chassis cell of a recombinant yeast strain, a mutant yeast strain is obtained by knocking out target genes PDC1 and ADH1, and weakening of an ethanol synthesis path is realized. On the basis, 7 alpha HSDH and 7 beta HSDH coding genes from clostridium are heterologously expressed, and the purpose of biosynthesis of UDCA by taking CDCA as a substrate is achieved. At present, the conversion rate of the substrate CDCA reaches 90%.

The invention relates to a method for a tetanus toxin receptor binding domain Hc to be subjected to high-level soluble expression in Escherichia coli through nucleotide sequence optimization. According to the sequencing result of a domestic C.Tetani virulent strain CMCC64008, the tetanus toxin receptor binding domain Hc sequence is analyzed and optimized, the optimized sequence is SEQ ID No.1 and the coded protein sequence is SEQ ID No.2. The synthesized Hc gene is linked into an expression vector pET32a(+) after undergoing double enzyme digestion, the recombinant Hc is subjected to high soluble expression in Escherichia coli and the target protein accounts for about 46% of the total protein in the supernatant undergoing bacteriociasis. After QFF column purification, phenyl hydrophobic column purification and SP column purification, the purity of the target protein can be more than 95% and the yield thereof is more than 300mg / L. The recombinant protein prepared by the method of the invention has good immunogenicity, can induce the mice to produce high-titre protective antibodies and can resist attack of high-dose lethal toxins. The method has extensive application prospect in large-scale high-level preparation of the tetanus toxin recombinant subunit vaccine Hc.

The invention relates to HSDH (hydroxysteroid dehydrogenase), in particular to a gene S1-a-1 of novel 7 alpha-HSDH. A nucleotide sequence of the gene is shown as SEQ ID NO.2, the novel 7 alpha-HSDH is encoded, a nucleotide sequence of the novel 7 alpha-HSDH is shown as SEQ ID NO.1, the novel 7 alpha-HSDH can be used for catalyzing CDCA (chenodeoxycholic acid) and TCDCA (taurochenodeoxycholic acid) to generate 7K-LCA (7-ketone lithocholic acid) and T7K-LCA (taurine-7-ketone lithocholic acid), wherein the catalytic activity of the novel 7 alpha-HSDH for CDCA is about 5 times of that of 7 alpha-HSDH of Sardinia clostridium, and the catalytic activity of the novel 7 alpha-HSDH for TCDCA is about over 2.5 times of that of 7 alpha-HSDH of Sardinia clostridium, therefore, the novel 7 alpha-HSDH has a great industrial application value.

A fixable oxycarbide and a microorganism capable of performing fermentation reaction and a preparation method and application thereof are characterized in that the preparation method includes: (a) providing a first parental generation bacterial strain capable of fixing the oxycarbide; (b) providing a second parental generation bacterial strain capable of performing the fermentation reaction; (c) respectively preparing the first parental generation bacterial strain and the second parental generation bacterial strain into a first protoplast and a second protoplast; (d) fusing the first protoplast and the second protoplast so as to provide a fused bacterial strain; and (e) cultivating the fused bacterial strain so as to obtain an object bacterial strain which can be used for producing organic compounds (such as organic acids and alcohols). A specific sample of the object bacterial strain is Colstridium tyrobutyricum strian ITRI02001 and is stored in Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). The storage number is DSM 32077.

The invention discloses a nano antibody for resisting glycosyl transferase A subunit and application of the nano antibody. A variable region of the nano antibody is provided with three complementary determining regions, namely CDR-1, CDR-2 and CDR-3, the CDR-1 is composed of an amino acid sequence as shown in SEQ ID NO.1, the CDR-2 is composed of an amino acid sequence as shown in SEQ ID NO.2, and the CDR-3 is composed of an amino acid sequence as shown in SEQ ID NO.3. The nano antibody for resisting the glycosyl transferase A subunit has the activity of being specifically bonded to the glycosyl transferase A subunit, neutralizes the activity of the glycosyl transferase A, can be used for detecting clostridium difficile and can also be used for preparing drugs for treating and resisting the clostridium difficile; the nano antibody also has the characteristics of small molecular weight, high affinity, stable structure and performance and the like; and the nano antibody has the advantages of being capable of tolerating the gastric acid environment and being not easily degraded by pepsin and the like.

The invention discloses recombinant alpha protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant alpha protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.353 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or / and amino terminals of the protein shown in (a) or (b). The recombinant alpha protein enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the recombinant alpha protein. The recombinant alpha protein is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.

The invention relates to hydroxysteroid dehydrogenase, in particular to a novel 7alpha-hydroxysteroid dehydrogenase gene S1-a-2. A nucleotide sequence of the gene is shown as SEQ ID NO.2. A novel 7alpha-hydroxysteroid dehydrogenase with an amino acid sequence shown as SEQ ID NO.1 is coded and is capable of catalyzing CDCA (chenodeoxycholic acid) and TCDCA (taurochenodeoxycholic acid) to generate 7K-LCA (7-ketone lithocholic acid) and T7K-LCA (tauro-7-keto lithocholic acid), catalytic activity of the novel 7alpha-hydroxysteroid dehydrogenase for the CDCA or TCDCA is about twice of that of Clostridium sardiniense 7alpha-HSDH for the same, and accordingly the novel 7alpha-hydroxysteroid dehydrogenase is high in industrial application value.

A VAMP epitope suitable for generating an antibody against a VAMP C-terminal neurotoxin cleavage product. Method of using such an epitope to generate an antibody against cleaved VAMP. Method of using such an antibody to assay for cleavage of a VAMP by clostridial neurotoxin.

Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.

The invention provides a method for improving the fermenting property of solventogenic clostridia. Specifically, the invention provides a nucleic acid construct first, wherein the nucleic acid construct contains amino acid sequences shown as coding SEQ ID NO:1,2,3 and 4, or polynucleotide sequences or the complementary sequences thereof of amino acid sequences which are subjected to substitution, deletion or adding of one or multiple amino acids in the amino acid sequences shown as the SEQ ID NO:1,2,3 and 4, respectively maintain the biological activity of the SEQ ID NO:1,2,3 and 4 and are respectively derived by the SEQ ID NO:1,2,3 and 4, and an optional promoter sequence creatively connected with the above polynucleotide sequences or the complementary sequences thereof. The invention also discloses the solventogenic clostridia, a method for fermentation by the solventogenic clostridia and a method for improving the growing ability and / or the solvent production ability of the solventogenic clostridia.

The invention relates to a hydroxysteroid dehydrogenase and particularly relates to a novel 7beta-hydroxysteroid dehydrogenase gene Y1-b-1. A nucleotide sequence of the gene is as shown in SEQ ID NO.2; a novel 7beta-hydroxysteroid dehydrogenase is encoded and an amino acid sequence thereof is as shown in SEQ ID NO.1. Epimerization of 7-hydroxy of ursodesoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA) can be catalyzed to generate intermediates 7-ketone lithocholic acid (7K-LCA) and taurine 7-ketone lithocholic acid (T7K-LCA) of chenodeoxycholic acid (CDCA) and taurochenodeoxycholic acid (TCDCA). The specific activity of the novel 7beta-hydroxysteroid dehydrogenase gene Y1-b-1 on the UDCA and the TUDCA is equivalent to that of existing clostridium sardiniense 7beta-HSDH, but the novel 7beta-hydroxysteroid dehydrogenase gene Y1-b-1 has better heat stability and a great industrial application prospect.

The present invention provides a method for the biological production of n-butanol at high yield from a fermentable carbon source. In one aspect of the present invention, a process for the conversion of glucose to n-butanol is achieved by the use of a recombinant organism comprising a host C. acetobutlicum transformed i) to eliminate the butyrate pathway ii) to eliminate the acetone pathway iii) to eliminate the lactate pathway and iv) to eliminate the acetate pathway. In another aspect of the present invention, the hydrogen flux is decreased and the reducing power redirected to n-butanol production by attenuating the expression of the hydrogenase gene. Optionally the n-butanol produced can be eliminated during the fermentation by gas striping and further purified by distillation.

The present invention relates to novel endolysin polypeptides or fragments thereof which possess antimicrobial activity, preferably antibacterial activity against Clostridium perfringens. The invention also relates to a nucleic acid molecule encoding the endolysin polypeptide or fragment, a recombinant polynucleotide expression vector comprising such a nucleic acid molecule, as well as a host cell comprising such a nucleic acid molecule or comprising such a recombinant polynucleotide expression vector. The invention also relates to compositions and foodstuffs comprising the endolysin polypeptides or fragments and uses thereof in the treatment of diseases or disorders in animals.